Pictet Asset Management Sa Pharvaris N.V. Transaction History

Pictet Asset Management Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.67 - $25.8 $481,330 - $1.62 Million	-62,755 Reduced 13.56%	399,875 $3.21 Million
Q2 2022 Aug 09, 2022	SELL	$16.35 - $27.5 $1.23 Million - $2.06 Million	-75,000 Reduced 13.95%	462,630 $10.2 Million
Q1 2022 May 13, 2022	SELL	$15.98 - $19.65 $50,832 - $62,506	-3,181 Reduced 0.59%	537,630 $10.1 Million
Q4 2021 Feb 10, 2022	SELL	$13.28 - $18.0 $215,773 - $292,464	-16,248 Reduced 2.92%	540,811 $8.56 Million
Q3 2021 Nov 12, 2021	BUY	$13.14 - $20.97 $7.32 Million - $11.7 Million	557,059 New	557,059 $9.61 Million

39.6M

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $687M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.